Ponstel

Ponstel is a brand name of mefenamic acid, approved by the FDA in the following formulation(s):

PONSTEL (mefenamic acid - capsule; oral)

• 
  Manufacturer: SHIONOGI INC
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 250MG ^[RLD][AB]

Has a generic version of Ponstel been approved?

Yes. The following products are equivalent to Ponstel:

mefenamic acid capsule; oral

• 
  Manufacturer: LUPIN LTD
  
  Approval date: July 22, 2011
  
  Strength(s): 250MG ^[AB]


• 
  Manufacturer: MICRO LABS LTD
  
  Approval date: November 19, 2010
  
  Strength(s): 250MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ponstel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ponstel.

See also...

• Ponstel Consumer Information (Wolters Kluwer)
• Ponstel Consumer Information (Cerner Multum)
• Ponstel Advanced Consumer Information (Micromedex)
• Ponstel AHFS DI Monographs (ASHP)
• Mefenamic Acid Consumer Information (Wolters Kluwer)
• Mefenamic acid Consumer Information (Cerner Multum)
• Mefenamic acid Advanced Consumer Information (Micromedex)
• Mefenamic Acid AHFS DI Monographs (ASHP)

Plan B One-Step

Plan B One-Step is a brand name of levonorgestrel, approved by the FDA in the following formulation(s):

PLAN B ONE-STEP (levonorgestrel - tablet; oral)

• 
  Manufacturer: DURAMED
  
  Approval date: July 10, 2009
  
  Strength(s): 1.5MG ^[RLD]

Has a generic version of Plan B One-Step been approved?

No. There is currently no therapeutically equivalent version of Plan B One-Step available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plan B One-Step. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Plan B One-Step.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 10, 2012 - NEW PRODUCT
  
  

See also...

• Plan B One-Step Consumer Information (Drugs.com)
• Plan B One-Step Consumer Information (Wolters Kluwer)
• Plan B One-Step Consumer Information (Cerner Multum)
• Plan B One-Step Oral Advanced Consumer Information (Micromedex)
• Levonorgestrel Consumer Information (Wolters Kluwer)
• Levonorgestrel IUD Consumer Information (Wolters Kluwer)
• Levonorgestrel Consumer Information (Cerner Multum)
• Levonorgestrel emergency contraceptive Consumer Information (Cerner Multum)
• Levonorgestrel intrauterine system Consumer Information (Cerner Multum)
• Levonorgestrel Advanced Consumer Information (Micromedex)
• Levonorgestrel Intrauterine Advanced Consumer Information (Micromedex)

Plaquenil

Plaquenil is a brand name of hydroxychloroquine, approved by the FDA in the following formulation(s):

PLAQUENIL (hydroxychloroquine sulfate - tablet; oral)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 200MG ^[RLD][AB]

Has a generic version of Plaquenil been approved?

Yes. The following products are equivalent to Plaquenil:

hydroxychloroquine sulfate tablet; oral

• 
  Manufacturer: IPCA LABS LTD
  
  Approval date: June 14, 2007
  
  Strength(s): 200MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: May 29, 1998
  
  Strength(s): 200MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: November 30, 1995
  
  Strength(s): 200MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: January 27, 1996
  
  Strength(s): 200MG ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: September 30, 1994
  
  Strength(s): 200MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: November 30, 1995
  
  Strength(s): 200MG ^[AB]


• 
  Manufacturer: WEST WARD
  
  Approval date: August 15, 2007
  
  Strength(s): 200MG ^[AB]


• 
  Manufacturer: ZYDUS PHARMS USA INC
  
  Approval date: September 21, 2007
  
  Strength(s): 200MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plaquenil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Plaquenil.

See also...

• Plaquenil Consumer Information (Drugs.com)
• Plaquenil Consumer Information (Wolters Kluwer)
• Plaquenil Sulfate Consumer Information (Cerner Multum)
• Plaquenil Advanced Consumer Information (Micromedex)
• Plaquenil AHFS DI Monographs (ASHP)
• Hydroxychloroquine Consumer Information (Wolters Kluwer)
• Hydroxychloroquine Consumer Information (Cerner Multum)
• Hydroxychloroquine Advanced Consumer Information (Micromedex)
• Hydroxychloroquine Sulfate AHFS DI Monographs (ASHP)

Imitrex

See also: Generic Imitrex Statdose

Imitrex is a brand name of sumatriptan, approved by the FDA in the following formulation(s):

IMITREX (sumatriptan succinate - injectable; subcutaneous)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: December 28, 1992
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[RLD][AP]

IMITREX (sumatriptan succinate - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: June 1, 1995
  
  Strength(s): EQ 100MG BASE ^[RLD][AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Has a generic version of Imitrex been approved?

Yes. The following products are equivalent to Imitrex:

sumatriptan succinate injectable; subcutaneous

• 
  Manufacturer: APP PHARMS
  
  Approval date: March 2, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: APP PHARMS
  
  Approval date: September 18, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: BEDFORD
  
  Approval date: February 6, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: BEDFORD LABS
  
  Approval date: August 11, 2010
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: JHP PHARMS
  
  Approval date: July 9, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: PAR PHARM
  
  Approval date: October 9, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: SAGENT STRIDES
  
  Approval date: June 10, 2010
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: SAGENT STRIDES
  
  Approval date: July 28, 2010
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: SANDOZ
  
  Approval date: February 6, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: TEVA PARENTERAL
  
  Approval date: February 6, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]


• 
  Manufacturer: WOCKHARDT
  
  Approval date: February 6, 2009
  
  Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

sumatriptan succinate tablet; oral

• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: DR REDDYS LABS INC
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: November 2, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: ORCHID HLTHCARE
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: RANBAXY
  
  Approval date: February 9, 2009
  
  Strength(s): EQ 100MG BASE ^[AB]


• 
  Manufacturer: RANBAXY
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: SUN PHARM INDS
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: February 9, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: August 10, 2009
  
  Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Imitrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Imitrex.

See also...

• Imitrex Consumer Information (Drugs.com)
• Imitrex Consumer Information (Wolters Kluwer)
• Imitrex Spray Consumer Information (Wolters Kluwer)
• Imitrex Tablets Consumer Information (Wolters Kluwer)
• Imitrex injection Consumer Information (Cerner Multum)
• Imitrex oral/nasal Consumer Information (Cerner Multum)
• Imitrex Advanced Consumer Information (Micromedex)
• Imitrex Oral Advanced Consumer Information (Micromedex)
• Imitrex Subcutaneous Advanced Consumer Information (Micromedex)
• Imitrex AHFS DI Monographs (ASHP)
• Sumatriptan Consumer Information (Wolters Kluwer)
• Sumatriptan Spray Consumer Information (Wolters Kluwer)
• Sumatriptan Tablets Consumer Information (Wolters Kluwer)
• Sumatriptan injection Consumer Information (Cerner Multum)
• Sumatriptan oral/nasal Consumer Information (Cerner Multum)
• Imitrex Stat Dose Refill Advanced Consumer Information (Micromedex)
• Imitrex Stat Dose Refill Subcutaneous Advanced Consumer Information (Micromedex)
• Sumatriptan Advanced Consumer Information (Micromedex)
• Sumatriptan Nasal, Oral, Subcutaneous Advanced Consumer Information (Micromedex)
• Sumatriptan Subcutaneous Advanced Consumer Information (Micromedex)
• Sumatriptan AHFS DI Monographs (ASHP)
• Sumatriptan Succinate AHFS DI Monographs (ASHP)

Paremyd

Paremyd is a brand name of hydroxyamphetamine/tropicamide ophthalmic, approved by the FDA in the following formulation(s):

PAREMYD (hydroxyamphetamine hydrobromide; tropicamide - solution/drops; ophthalmic)

• 
  Manufacturer: AKORN
  
  Approval date: January 30, 1992
  
  Strength(s): 1%;0.25% ^[RLD]

Has a generic version of Paremyd been approved?

No. There is currently no therapeutically equivalent version of Paremyd available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Paremyd. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Paremyd.

See also...

• Paremyd Consumer Information (Wolters Kluwer)
• Paremyd Ophthalmic Advanced Consumer Information (Micromedex)
• Hydroxyamphetamine/Tropicamide Consumer Information (Wolters Kluwer)
• Hydroxyamphetamine and tropicamide Ophthalmic Advanced Consumer Information (Micromedex)

Zofran ODT

See also: Generic Zofran

Zofran ODT is a brand name of ondansetron, approved by the FDA in the following formulation(s):

ZOFRAN ODT (ondansetron - tablet, orally disintegrating; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: January 27, 1999
  
  Strength(s): 4MG ^[AB], 8MG ^[RLD][AB]

Has a generic version of Zofran ODT been approved?

A generic version of Zofran ODT has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zofran ODT and have been approved by the FDA:

ondansetron tablet, orally disintegrating; oral

• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: April 12, 2010
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: BARR
  
  Approval date: June 25, 2007
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: June 27, 2007
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: June 25, 2007
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: NESHER PHARMS
  
  Approval date: June 25, 2007
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: PAR PHARM
  
  Approval date: December 26, 2006
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: RANBAXY
  
  Approval date: February 24, 2011
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: August 13, 2007
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: SUN PHARM INDS
  
  Approval date: August 2, 2007
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: June 25, 2007
  
  Strength(s): 4MG ^[AB], 8MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zofran ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Freeze-dried compositions
  Patent 5,955,488
  Issued: September 21, 1999
  Inventor(s): Winterborn; Ian Keith
  Assignee(s): Glaxo Wellcome Inc.
  The invention relates to a freeze-dried dosage form for oral administration capable of being rapidly disintegrated in the mouth comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5HT) at 5HT.sub.3 receptors are also described.
  
  Patent expiration dates:
  
  
  • November 14, 2015
    
  
  
  
  • May 14, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Ondansetron freeze-dried dosage form compositions for oral administration
  Patent 6,063,802
  Issued: May 16, 2000
  Inventor(s): Winterborn; Ian Keith
  Assignee(s): Glaxco Wellcome Inc.
  The invention relates to a freeze-dried dosage form for oral administration capable of being rapidly disintegrated in the mouth comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5HT) at 5HT.sub.3 receptors are also described.
  
  Patent expiration dates:
  
  
  • November 14, 2015
    
  
  
  
  • May 14, 2016
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Zofran ODT Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Zofran ODT Consumer Information (Cerner Multum)
• Zofran ODT Advanced Consumer Information (Micromedex)
• Zofran ODT Oral, Oromucosal Advanced Consumer Information (Micromedex)
• Ondansetron Consumer Information (Drugs.com)
• Ondansetron Consumer Information (Wolters Kluwer)
• Ondansetron Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Ondansetron Soluble Film Consumer Information (Wolters Kluwer)
• Ondansetron Solution Consumer Information (Wolters Kluwer)
• Ondansetron Tablets Consumer Information (Wolters Kluwer)
• Ondansetron Consumer Information (Cerner Multum)
• Ondansetron injection Consumer Information (Cerner Multum)
• Ondansetron Oral, Injection, Intravenous Advanced Consumer Information (Micromedex)
• Ondansetron Oral, Oromucosal Advanced Consumer Information (Micromedex)
• Ondansetron Hydrochloride AHFS DI Monographs (ASHP)

Androderm

See also: Generic AndroGel

Androderm is a brand name of testosterone, approved by the FDA in the following formulation(s):

ANDRODERM (testosterone - film, extended release; transdermal)

• 
  Manufacturer: WATSON LABS
  
  Approval date: October 20, 2011
  
  Strength(s): 2MG/24HR ^[RLD], 4MG/24HR ^[RLD]

Has a generic version of Androderm been approved?

No. There is currently no therapeutically equivalent version of Androderm available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Androderm. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Androderm.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 20, 2014 - NEW STRENGTH
  
  

See also...

• Androderm Patch Consumer Information (Wolters Kluwer)
• Androderm Consumer Information (Cerner Multum)
• Androderm Advanced Consumer Information (Micromedex)
• Testosterone Consumer Information (Drugs.com)
• Testosterone Consumer Information (Wolters Kluwer)
• Testosterone Gel Consumer Information (Wolters Kluwer)
• Testosterone Patch Consumer Information (Wolters Kluwer)
• Testosterone Solution Consumer Information (Wolters Kluwer)
• Testosterone buccal system Consumer Information (Cerner Multum)
• Testosterone injection Consumer Information (Cerner Multum)
• Testosterone topical Consumer Information (Cerner Multum)
• Androplex Advanced Consumer Information (Micromedex)
• Testosterone Buccal Advanced Consumer Information (Micromedex)
• Testosterone Topical application Advanced Consumer Information (Micromedex)
• Testosterone Transdermal Advanced Consumer Information (Micromedex)
• Testosterone AHFS DI Monographs (ASHP)